570 related articles for article (PubMed ID: 29607963)
1. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
[TBL] [Abstract][Full Text] [Related]
2. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
Kogiso T; Kobayashi M; Yamamoto K; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
Intern Med; 2017 Nov; 56(22):2993-3001. PubMed ID: 28943585
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
[TBL] [Abstract][Full Text] [Related]
4. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
[TBL] [Abstract][Full Text] [Related]
5. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
[TBL] [Abstract][Full Text] [Related]
6. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
[TBL] [Abstract][Full Text] [Related]
7. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
[TBL] [Abstract][Full Text] [Related]
8. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
Pose E; Solà E; Piano S; Gola E; Graupera I; Guevara M; Cárdenas A; Angeli P; Ginès P
Am J Med; 2017 Mar; 130(3):372-375. PubMed ID: 27746291
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
10. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
11. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
[TBL] [Abstract][Full Text] [Related]
12. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
15. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS;
Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645
[TBL] [Abstract][Full Text] [Related]
16. Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report.
Parekh A; Rajaram P; Patel G; Subramanian RM
Transplant Proc; 2017 Dec; 49(10):2399-2401. PubMed ID: 29198689
[TBL] [Abstract][Full Text] [Related]
17. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
[TBL] [Abstract][Full Text] [Related]
19. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
Gaglio P; Marfo K; Chiodo J
Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
[TBL] [Abstract][Full Text] [Related]
20. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
